show 92 more results
-84.6% (n=57) vs 209.3% (n=60) placebo @ 4wk50 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-79.9% (n=57) vs 146.3% (n=60) placebo @ 8wk50 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-73.2% (n=57) vs 122.2% (n=60) placebo @ 12wk50 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-87.1% (n=57) vs 134.4% (n=60) placebo @ 16wk50 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-84% (n=57) vs 118.8% (n=60) placebo @ 20wk50 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-79.4% (n=57) vs 114.2% (n=60) placebo @ 24wk50 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-74.7% (n=57) vs 140.2% (n=60) placebo @ 28wk50 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-59.9% (n=57) vs 152% (n=60) placebo @ 36wk50 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-48.3% (n=57) vs 135.8% (n=60) placebo @ 48wk50 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-83.2% (n=57) vs 7% (n=57) placebo @ 4wk50 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-78.7% (n=57) vs 4.7% (n=57) placebo @ 8wk50 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-72.2% (n=57) vs 0% (n=57) placebo @ 12wk50 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-86.3% (n=57) vs 2.8% (n=57) placebo @ 16wk50 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-82.6% (n=57) vs 7.8% (n=57) placebo @ 20wk50 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-78.2% (n=57) vs -0.8% (n=57) placebo @ 24wk50 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-73.2% (n=57) vs -2.2% (n=57) placebo @ 28wk50 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-58.3% (n=57) vs 0.2% (n=57) placebo @ 36wk50 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-46.8% (n=57) vs 5.6% (n=57) placebo @ 48wk50 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-65.7% (n=62) vs 23.9% (n=79) placebo @ 24wk50 mg Q12W
NCT04998201 · Phase 2 · registry result, not featured evidence
-57.9% (n=61) vs 23.9% (n=79) placebo @ 24wk50 mg Q24W
NCT04998201 · Phase 2 · registry result, not featured evidence
-78.4% (n=64) vs 19.3% (n=84) placebo @ 4wk50 mg Q12W
NCT04998201 · Phase 2 · registry result, not featured evidence
-82.7% (n=65) vs 19.3% (n=84) placebo @ 4wk50 mg Q24W
NCT04998201 · Phase 2 · registry result, not featured evidence
-71.8% (n=64) vs 19% (n=84) placebo @ 8wk50 mg Q12W
NCT04998201 · Phase 2 · registry result, not featured evidence
-78.1% (n=65) vs 19% (n=84) placebo @ 8wk50 mg Q24W
NCT04998201 · Phase 2 · registry result, not featured evidence
-59.2% (n=64) vs 20.3% (n=84) placebo @ 12wk50 mg Q12W
NCT04998201 · Phase 2 · registry result, not featured evidence
-71.5% (n=65) vs 20.3% (n=84) placebo @ 12wk50 mg Q24W
NCT04998201 · Phase 2 · registry result, not featured evidence
-78.9% (n=64) vs 10.9% (n=84) placebo @ 16wk50 mg Q12W
NCT04998201 · Phase 2 · registry result, not featured evidence
-67.7% (n=65) vs 10.9% (n=84) placebo @ 16wk50 mg Q24W
NCT04998201 · Phase 2 · registry result, not featured evidence
-69.3% (n=64) vs 21.8% (n=84) placebo @ 20wk50 mg Q12W
NCT04998201 · Phase 2 · registry result, not featured evidence
-62.6% (n=65) vs 21.8% (n=84) placebo @ 20wk50 mg Q24W
NCT04998201 · Phase 2 · registry result, not featured evidence
-65.7% (n=64) vs 23.9% (n=84) placebo @ 24wk50 mg Q12W
NCT04998201 · Phase 2 · registry result, not featured evidence
-57.9% (n=65) vs 23.9% (n=84) placebo @ 24wk50 mg Q24W
NCT04998201 · Phase 2 · registry result, not featured evidence
-53.3% (n=64) vs 35.6% (n=84) placebo @ 28wk50 mg Q12W
NCT04998201 · Phase 2 · registry result, not featured evidence
-82.5% (n=65) vs 35.6% (n=84) placebo @ 28wk50 mg Q24W
NCT04998201 · Phase 2 · registry result, not featured evidence
-34.5% (n=64) vs 30.6% (n=84) placebo @ 36wk50 mg Q12W
NCT04998201 · Phase 2 · registry result, not featured evidence
-75.8% (n=65) vs 30.6% (n=84) placebo @ 36wk50 mg Q24W
NCT04998201 · Phase 2 · registry result, not featured evidence
-73.7% (n=54) vs 114.2% (n=59) placebo @ 24wk25 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-84.4% (n=55) vs 209.3% (n=60) placebo @ 4wk25 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-78.8% (n=55) vs 146.3% (n=60) placebo @ 8wk25 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-71.8% (n=55) vs 122.2% (n=60) placebo @ 12wk25 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-86.4% (n=55) vs 134.4% (n=60) placebo @ 16wk25 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-81.2% (n=55) vs 118.8% (n=60) placebo @ 20wk25 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-73.7% (n=55) vs 114.2% (n=60) placebo @ 24wk25 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-71.9% (n=55) vs 140.2% (n=60) placebo @ 28wk25 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-60.9% (n=55) vs 152% (n=60) placebo @ 36wk25 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-49.6% (n=55) vs 135.8% (n=60) placebo @ 48wk25 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-82.9% (n=55) vs 7% (n=57) placebo @ 4wk25 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-77.2% (n=55) vs 4.7% (n=57) placebo @ 8wk25 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-70.3% (n=55) vs 0% (n=57) placebo @ 12wk25 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-84.9% (n=55) vs 2.8% (n=57) placebo @ 16wk25 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-79.7% (n=55) vs 7.8% (n=57) placebo @ 20wk25 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-72.1% (n=55) vs -0.8% (n=57) placebo @ 24wk25 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-70.2% (n=55) vs -2.2% (n=57) placebo @ 28wk25 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-59.1% (n=55) vs 0.2% (n=57) placebo @ 36wk25 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-48% (n=55) vs 5.6% (n=57) placebo @ 48wk25 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-44.3% (n=63) vs 23.9% (n=79) placebo @ 24wk25 mg Q12W
NCT04998201 · Phase 2 · registry result, not featured evidence
-69.7% (n=67) vs 19.3% (n=84) placebo @ 4wk25 mg Q12W
NCT04998201 · Phase 2 · registry result, not featured evidence
-61.9% (n=67) vs 19% (n=84) placebo @ 8wk25 mg Q12W
NCT04998201 · Phase 2 · registry result, not featured evidence
-18.9% (n=67) vs 20.3% (n=84) placebo @ 12wk25 mg Q12W
NCT04998201 · Phase 2 · registry result, not featured evidence
-63.8% (n=67) vs 10.9% (n=84) placebo @ 16wk25 mg Q12W
NCT04998201 · Phase 2 · registry result, not featured evidence
-63.3% (n=67) vs 21.8% (n=84) placebo @ 20wk25 mg Q12W
NCT04998201 · Phase 2 · registry result, not featured evidence
-44.3% (n=67) vs 23.9% (n=84) placebo @ 24wk25 mg Q12W
NCT04998201 · Phase 2 · registry result, not featured evidence
-32.8% (n=67) vs 35.6% (n=84) placebo @ 28wk25 mg Q12W
NCT04998201 · Phase 2 · registry result, not featured evidence
-24.9% (n=67) vs 30.6% (n=84) placebo @ 36wk25 mg Q12W
NCT04998201 · Phase 2 · registry result, not featured evidence
-69.6% (n=49) vs 114.2% (n=59) placebo @ 24wk10 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-67.3% (n=54) vs 209.3% (n=60) placebo @ 4wk10 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-59.8% (n=54) vs 146.3% (n=60) placebo @ 8wk10 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-55.5% (n=54) vs 122.2% (n=60) placebo @ 12wk10 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-77.1% (n=54) vs 134.4% (n=60) placebo @ 16wk10 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-71.7% (n=54) vs 118.8% (n=60) placebo @ 20wk10 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-69.6% (n=54) vs 114.2% (n=60) placebo @ 24wk10 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-64.4% (n=54) vs 140.2% (n=60) placebo @ 28wk10 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-50.2% (n=54) vs 152% (n=60) placebo @ 36wk10 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-34.5% (n=54) vs 135.8% (n=60) placebo @ 48wk10 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-65.1% (n=53) vs 7% (n=57) placebo @ 4wk10 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-57.3% (n=53) vs 4.7% (n=57) placebo @ 8wk10 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-53.2% (n=53) vs 0% (n=57) placebo @ 12wk10 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-74.8% (n=53) vs 2.8% (n=57) placebo @ 16wk10 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-69.9% (n=53) vs 7.8% (n=57) placebo @ 20wk10 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-68.1% (n=53) vs -0.8% (n=57) placebo @ 24wk10 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-63% (n=53) vs -2.2% (n=57) placebo @ 28wk10 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-48.5% (n=53) vs 0.2% (n=57) placebo @ 36wk10 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-33.7% (n=53) vs 5.6% (n=57) placebo @ 48wk10 mg
NCT04720534 · Phase 2 · registry result, not featured evidence
-58.9% (n=59) vs 23.9% (n=79) placebo @ 24wk10 mg Q12W
NCT04998201 · Phase 2 · registry result, not featured evidence
-60.7% (n=63) vs 19.3% (n=84) placebo @ 4wk10 mg Q12W
NCT04998201 · Phase 2 · registry result, not featured evidence
-57.3% (n=63) vs 19% (n=84) placebo @ 8wk10 mg Q12W
NCT04998201 · Phase 2 · registry result, not featured evidence
-48.7% (n=63) vs 20.3% (n=84) placebo @ 12wk10 mg Q12W
NCT04998201 · Phase 2 · registry result, not featured evidence
-69.9% (n=63) vs 10.9% (n=84) placebo @ 16wk10 mg Q12W
NCT04998201 · Phase 2 · registry result, not featured evidence
-64% (n=63) vs 21.8% (n=84) placebo @ 20wk10 mg Q12W
NCT04998201 · Phase 2 · registry result, not featured evidence
-58.9% (n=63) vs 23.9% (n=84) placebo @ 24wk10 mg Q12W
NCT04998201 · Phase 2 · registry result, not featured evidence
-51.7% (n=63) vs 35.6% (n=84) placebo @ 28wk10 mg Q12W
NCT04998201 · Phase 2 · registry result, not featured evidence
-46.3% (n=63) vs 30.6% (n=84) placebo @ 36wk10 mg Q12W
NCT04998201 · Phase 2 · registry result, not featured evidence